Literature DB >> 18077447

Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin.

Moh'd A Salameh1, Alexei S Soares, Alexandra Hockla, Evette S Radisky.   

Abstract

Human mesotrypsin is an isoform of trypsin that displays unusual resistance to polypeptide trypsin inhibitors and has been observed to cleave several such inhibitors as substrates. Whereas substitution of arginine for the highly conserved glycine 193 in the trypsin active site has been implicated as a critical factor in the inhibitor resistance of mesotrypsin, how this substitution leads to accelerated inhibitor cleavage is not clear. Bovine pancreatic trypsin inhibitor (BPTI) forms an extremely stable and cleavage-resistant complex with trypsin, and thus provides a rigorous challenge of mesotrypsin catalytic activity toward polypeptide inhibitors. Here, we report kinetic constants for mesotrypsin and the highly homologous (but inhibitor sensitive) human cationic trypsin, describing inhibition by, and cleavage of BPTI, as well as crystal structures of the mesotrypsin-BPTI and human cationic trypsin-BPTI complexes. We find that mesotrypsin cleaves BPTI with a rate constant accelerated 350-fold over that of human cationic trypsin and 150,000-fold over that of bovine trypsin. From the crystal structures, we see that small conformational adjustments limited to several side chains enable mesotrypsin-BPTI complex formation, surmounting the predicted steric clash introduced by Arg-193. Our results show that the mesotrypsin-BPTI interface favors catalysis through (a) electrostatic repulsion between the closely spaced mesotrypsin Arg-193 and BPTI Arg-17, and (b) elimination of two hydrogen bonds between the enzyme and the amine leaving group portion of BPTI. Our model predicts that these deleterious interactions accelerate leaving group dissociation and deacylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077447     DOI: 10.1074/jbc.M708268200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor.

Authors:  Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh
Journal:  J Biochem       Date:  2010-07-20       Impact factor: 3.387

2.  Functional and structural roles of the Cys14-Cys38 disulfide of bovine pancreatic trypsin inhibitor.

Authors:  Elena Zakharova; Martin P Horvath; David P Goldenberg
Journal:  J Mol Biol       Date:  2008-07-30       Impact factor: 5.469

Review 3.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

4.  Complex Formation of Human Proelastases with Procarboxypeptidases A1 and A2.

Authors:  András Szabó; Claudia Pilsak; Melinda Bence; Heiko Witt; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

5.  The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.

Authors:  Moh'd A Salameh; Jessica L Robinson; Duraiswamy Navaneetham; Dipali Sinha; Benjamin J Madden; Peter N Walsh; Evette S Radisky
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

6.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

7.  Zymogen activation confers thermodynamic stability on a key peptide bond and protects human cationic trypsin from degradation.

Authors:  András Szabó; Evette S Radisky; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

8.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

9.  Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.

Authors:  Itay Cohen; Matt Coban; Anat Shahar; Banumathi Sankaran; Alexandra Hockla; Shiran Lacham; Thomas R Caulfield; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

10.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.